{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:29:25Z","timestamp":1793788165938,"version":"4.6.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,11,4]],"date-time":"2027-11-04T00:00:00Z","timestamp":1825286400000},"content-version":"am","delay-in-days":399,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009416","name":"The University of Chicago Bucksbaum Institute for Clinical Excellence","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urology.2026.08.037","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:56:05Z","timestamp":1788278165000},"page":"53-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rising Active Surveillance\/Observation Rates and Regimen Intensification in Young Men: A Retrospective Cohort Study of National Commercial Health Insurance Claims Data"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1755-5742","authenticated-orcid":false,"given":"J. Bradley","family":"Mason","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9829-5868","authenticated-orcid":false,"given":"Max J.","family":"Hyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted A.","family":"Skolarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5754-4445","authenticated-orcid":false,"given":"Parth K.","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2026.08.037_bib1","unstructured":"Cancer Stat Facts: Prostate Cancer. Accessed August 28, 2025. seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"10.1016\/j.urology.2026.08.037_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.08.037_bib3","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1186\/s12889-025-24808-4","article-title":"A population-based survey of self-reported and IIEF-defined erectile dysfunction among adult men in the United States in 2021","volume":"25","author":"Amand","year":"2025","journal-title":"BMC Public Health"},{"key":"10.1016\/j.urology.2026.08.037_bib4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/jama.2025.7045","article-title":"Lower urinary tract symptoms in men: a review","volume":"334","author":"Wei","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2026.08.037_bib5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.juro.2018.08.023","article-title":"Older age predicts biopsy and radical prostatectomy grade reclassification to aggressive prostate cancer in men on active surveillance","volume":"201","author":"Druskin","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.08.037_bib6","doi-asserted-by":"crossref","first-page":"432.e1","DOI":"10.1016\/j.urolonc.2020.11.024","article-title":"Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer","volume":"39","author":"Liu","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2026.08.037_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1439","article-title":"Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US","volume":"6","author":"Cooperberg","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urology.2026.08.037_bib8","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/jama.2018.5616","article-title":"Use of conservative management for low-risk prostate cancer in the veterans affairs integrated health care system from 2005-2015","volume":"319","author":"Loeb","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2026.08.037_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.6695","article-title":"Long-term outcomes in patients using protocol-directed active surveillance for prostate cancer","volume":"331","author":"Newcomb","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2026.08.037_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1001\/jama.2018.19941","article-title":"Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010-2015","volume":"321","author":"Mahal","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2026.08.037_bib11","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2016.68.0058","article-title":"Active surveillance in younger men with prostate cancer","volume":"35","author":"Leapman","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2026.08.037_bib12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/JU.0000000000000031","article-title":"Active surveillance of prostate cancer is a viable option for men younger than 60 years","volume":"201","author":"Salari","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.08.037_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eururo.2014.08.024","article-title":"Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer","volume":"67","author":"Womble","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.08.037_bib14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.juro.2016.02.2963","article-title":"How active is active surveillance? Intensity of followup during active surveillance for prostate cancer in the United States","volume":"196","author":"Loeb","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.08.037_bib15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41391-022-00580-z","article-title":"Intensity of observation with active surveillance or watchful waiting in men with prostate cancer in the United States","volume":"26","author":"Al Awamlh","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urology.2026.08.037_bib16","first-page":"569","article-title":"Implications of evolving delivery system reforms for prostate cancer care","volume":"22","author":"Hollenbeck","year":"2017","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.urology.2026.08.037_bib17","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1001\/jama.2024.20580","article-title":"Active surveillance or watchful waiting for intermediate-risk prostate cancer, 2010-2020","volume":"332","author":"Ajjawi","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2026.08.037_bib18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.urology.2018.06.037","article-title":"National trends in active surveillance for prostate cancer: validation of Medicare claims-based algorithms","volume":"120","author":"Modi","year":"2018","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.urology.2026.08.037_bib19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort","volume":"77","author":"Tosoian","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.08.037_bib20","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2016.03.048","article-title":"Long-term results of active surveillance in the G\u00f6teborg randomized, population-based prostate cancer screening trial","volume":"70","author":"Godtman","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.08.037_bib21","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2026.08.037_bib22","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2026.08.037_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/jamaoncol.2016.5465","article-title":"Increase in prostate cancer distant metastases at diagnosis in the United States","volume":"3","author":"Hu","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urology.2026.08.037_bib24","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2026.08.037_bib25","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/cncr.31337","article-title":"PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening","volume":"124","author":"Kearns","year":"2018","journal-title":"Cancer"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526005509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526005509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:04:29Z","timestamp":1793786669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429526005509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"alternative-id":["S0090429526005509"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2026.08.037","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rising Active Surveillance\/Observation Rates and Regimen Intensification in Young Men: A Retrospective Cohort Study of National Commercial Health Insurance Claims Data","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2026.08.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}